comparemela.com

Onis Onxeo News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Onxeo S A : Onxeo: Combined General Meeting of June 6, 2023: Availability of Preparatory Documents and Participation & Voting Procedures

Regulatory News: Onxeo S.A. (Euronext Growth Paris: ALONX), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR) and

France generalOnxeo sa euronextOnis onxeoArthur rouillNicolas fossiezGewinn nurRaymond poincarRenaissance paris nobel tour eiffel hotelCompany groupRegulatory newsEuronext growth parisCombined general meetingGeneral meetingGeneral meetingsInvestor relations

Onxeo S A : Onxeo will publish its full-year results on April 24, 2023

Regulatory News: Onxeo S.A. (Euronext Growth Paris: ALONX), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR) and

France generalOnxeo sa euronextOnis onxeoNicolas fossiezArthur rouillCompany groupRegulatory newsEuronext growth parisMonday april

Onxeo Will Publish Its Full-year Results on April 21, 2023

Regulatory News: Onxeo S.A. (Euronext Growth Paris: ALONX) (Paris:ALONX), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response

France generalOnis onxeoArthur rouillNicolas fossiezOnxeo sa euronextCompany groupRegulatory newsEuronext growth paris

Onxeo Will Publish Its Full-year Results on April 14, 2023

The annual general meeting will be held on June 6, 2023 Regulatory News: Onxeo S.A. (Euronext Growth Paris: ALONX) (Paris:ALONX), a clinical-stage biotechnology company specializing in the development

France generalDennis riedlArthur rouillOnis onxeoNicolas fossiezOnxeo sa euronextCompany board of directorsCompany groupEuronext growth paris

Onxeo S A : Onxeo: Report on the Extraordinary General Meeting of February 6, 2023

Regulatory News: Onxeo S.A. (Euronext Growth Paris: ALONX), ("Onxeo" or "the Company"), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor

France generalArthur rouillOnis onxeoNicolas fossiezOnxeo sa euronextSchwierige zeitenCompany groupRegulatory newsEuronext growth parisExtraordinary general meetingGeneral meetingGeneral meetings

vimarsana © 2020. All Rights Reserved.